

**Culture Environment Regulates Amino Acid Turnover and Glucose Utilisation in
Human ES Cells**

Joy Rathjen^{1,2}, Christine Yeo¹, Charlotte Yap¹, Boon Siang Nicholas Tan¹, Peter D.
Rathjen^{1,2} and David K. Gardner^{1*}

¹Department of Zoology, University of Melbourne, 3010, Victoria, Australia, ² Menzies
Research Institute Tasmania, University of Tasmania, 17 Liverpool Street, Hobart, 7000,
Tasmania, Australia.

*Address correspondence to Prof. David Gardner, Department of Zoology, University of
Melbourne, Parkville, VIC 3010, Australia +613 8344 6259. Email:
david.gardner@unimelb.edu.au

Running title: Culture environment regulates human ES cells

Keywords: human embryonic stem cells, metabolomics, amino acid turnover,
carbohydrate use, pluripotency

1 **Abstract**

2 Human embryonic stem (ES) cells have been proposed as a renewable source of
3 pluripotent cells that can be differentiated into various cell types for use in research, drug
4 discovery and in the emerging area of regenerative medicine. Exploitation of this
5 potential will require the development of ES cell culture conditions that promote
6 pluripotency and a normal cell metabolism, and quality control parameters that measure
7 these outcomes. There is, however, relatively little known about the metabolism of
8 pluripotent cells or the impact of culture environment and differentiation on their
9 metabolic pathways. We have examined the effect of two commonly used medium
10 supplements and cell differentiation on metabolic indicators in human ES cells. Medium
11 modifications and differentiation were compared in a chemically defined and feeder
12 independent culture system. Adding serum increased glucose utilisation and altered
13 amino acid turnover by the cells, as well as inducing a small proportion of the cells to
14 differentiate. Cell differentiation could be mitigated by inhibiting p38 MAPK activity.
15 The addition of Knock Out Serum Replacer[®] also increased glucose uptake and changed
16 amino acid turnover by the cells. These changes were distinct from those induced by
17 serum and occurred in the absence of detectable differentiation. Induction of
18 differentiation by BMP4, in contrast, did not alter metabolite turnover. Deviations from
19 metabolite turnover by ES cells in fully defined medium demonstrated that culture
20 environment can alter metabolite use. The challenge remains to understand the impact of
21 metabolic changes on long-term cell maintenance and the functionality of derived cell
22 populations.

23 **Introduction**

24 Pluripotent cell lines derived from the human blastocyst, human embryonic stem (ES)
25 cells, were first described in 1998 (Thomson *et al.* 1998; Reubinoff *et al.* 2000). In the
26 intervening years the isolation of more than 200 individual human ES cell lines has been
27 reported (reviewed in (Adewumi *et al.* 2007)). Despite the varied genetic background of
28 these isolates, and the diversity of clinics and laboratory conditions involved in their
29 isolation, these cells show a remarkable consistency with regards to pluripotent cell
30 marker expression (Adewumi *et al.* 2007). They retain a broad differentiation potential in
31 culture, capable of generating cell populations consistent with derivatives of the three
32 primary germ lineages and the extraembryonic endoderm. The cells can be propagated
33 indefinitely while maintaining a normal karyotype and express genetic markers and cell
34 surface antigens correlated with pluripotency, including *OCT4*, *NANOG*, *TDGF*, *GDF*,
35 *DNMT3B*, *FGF4*, *GCTM2* and *TRA1-60/TRA1-81* (Adewumi *et al.* 2007). To date, the
36 evaluation of human ES cell lines has focused on assessing parameters that are associated
37 with cell function, or pluripotency. In contrast, little emphasis has been placed on
38 characterizing the physiology of these cells. Given that appropriately regulated
39 metabolism is fundamental to cell function and viability, it is paramount that a greater
40 understanding of metabolic events that occur during stem cell derivation, culture and
41 differentiation is developed. Application of this knowledge will underpin the
42 development of propagation media and protocols that ensure maintenance of cell state
43 and cell physiology. Cell physiology markers are not currently employed for the appraisal
44 of human ES cells in culture or in the development of human ES cell culture medium.

45 The physiology of the early embryo, from which ES cells are routinely derived, has been
46 extensively characterized. Perturbation of the metabolism of the preimplantation embryo
47 significantly impairs subsequent embryo implantation and development (Lane and
48 Gardner 1996; Gardner 1998). Embryonic metabolism is sensitive to the composition of
49 culture medium. Serum, a common addition to culture media, has been shown to damage
50 blastomere ultrastructure, specifically affecting mitochondrial state and function
51 (Thompson *et al.* 1995). As a consequence, oxidative function is compromised, gene
52 expression and imprinting affected and embryo development impaired (Khosla *et al.*
53 2001). Subsequent fetal development in laboratory and domestic animals is associated
54 with compromised outcomes, demonstrating that altered physiology at the
55 preimplantation embryo stage, induced by the culture medium, has significant
56 downstream effects (Thompson *et al.* 1995; Gardner 1998; Lane and Gardner 2005).
57 Early alterations in physiology likely impact later developmental through interaction with
58 the epigenetic programming that occurs at this stage in development and causing the
59 establishment of epigenetic marks that impinge on later life (Donohoe and Bultman
60 2012). The development of culture media designed to maintain normal embryo
61 physiology and function, coupled with the development of metabolic markers of
62 embryonic viability (Gardner 1998; Sakkas and Gardner 2005; Gardner 2011) has
63 resulted in improvements in embryo quality in culture and concomitant improvements in
64 outcomes from assisted reproductive technologies in laboratory and domestic animals and
65 in humans (Oddens 2006).

66 Understanding the environmental requirements for the optimal maintenance of human ES
67 cells in culture will require knowledge not only of the signaling pathways that regulate

68 pluripotency and differentiation but also, and of equal significance, of the specific
69 nutrient requirements of the cell and how the metabolome is affected by different
70 environmental conditions and states of differentiation. One of the limitations of
71 characterizing human ES cell physiology is the diversity of medium and supplements that
72 are routinely used in the culture of these cells coupled with a lack of systematic
73 assessment of how human ES cells respond to the culture environment. Here we
74 characterize glucose use and amino acid turnover in human ES cells in culture; both of
75 these parameters have been used to assess embryo quality and can be correlated with
76 improved embryo outcome (Lane and Gardner 1996; Houghton *et al.* 2002; Brison *et al.*
77 2004; Gardner 2011; Gardner *et al.* 2011). The addition of serum (20%), or Knockout
78 Serum Replacer (Knockout™ SR; Life Technologies; 20%), to a chemically-defined
79 human ES cell culture system resulted in altered amino acid turnover, increased uptake
80 and metabolism of glucose and increased cell loss from the population. These changes
81 did not correlate with the level of pluripotency, extent of differentiation in the cultures or
82 with changes in cell proliferation. In contrast, induction of differentiation by BMP4 in
83 this system had little effect on glucose uptake and metabolism or amino acid turnover.
84 These data demonstrate that in human ES cells metabolic indicators can be affected
85 significantly by the culture environment and suggest that the cells can experience stress in
86 response to sub-optimal culture conditions. Before the full realization of the clinical and
87 commercial potential of human ES cells can be achieved the impact of altering cell
88 metabolism on viability and function needs to be understood.

89

90 **Materials and Methods**

91 *Human ES cell culture*

92 The human ES cell line, MEL-2 (Australian Stem Cell Centre), was cultured in mTeSR1
93 medium (STEMCELL Technologies) (Ludwig *et al.* 2006a; Ludwig *et al.* 2006b), on
94 human ES cell-qualified Matrigel™ (BD Biosciences), as per the manufacturer's
95 instructions. Cells were passaged every 7 days using Dispase (STEMCELL
96 Technologies) at 37°C. Cell clumps were resuspended in mTeSR1 medium and plated at
97 a ratio of 1:6 to 1:10 in 6 or 12 well cluster dishes (Falcon, Becton, Dickinson and
98 Company). Cells were cultured at 37°C in 5% CO₂ in ambient air in a Galaxy R incubator
99 (RS Biotech). Foetal calf sera (sourced from Invitrogen and Hyclone) and Knock-out
100 Serum Replacer (Knockout™ SR; Invitrogen) were added after 72 hours (FCS and
101 Knockout™ SR) or 144 hours (FCS) and replaced daily until day 7, or 168 hours.
102 SB203580 (Sigma Aldrich) was added after 72 hours to a concentration of 10 µM; a
103 commensurate volume of diluent (DMSO) was added to controls. Medium was replaced
104 at a similar time each day. Each experiment was set up in triplicate and triplicate wells
105 were treated as a covariate in statistical analysis. On completion of cell culture and after
106 medium collection cells were incubated with TrypLE Select (Life Technologies) for 8
107 minutes at 37°C, triturated to a single cell suspension and counted on a haemocytometer.
108 Images of human ES cells were captured on an Olympus IX50 inverted microscope.

109 **Real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)**

110 Total RNA was extracted from human ES cells with an RNAqueous-4PCR Kit (Ambion)
111 according to the manufacturer's instructions. RNA was DNaseI treated (Ambion) and
112 cDNA was synthesized with M-MLV Reverse Transcriptase (Promega) and oligo(dT)

113 primers (Promega). Real-time PCR reactions were set up in triplicate using Absolute
114 Blue QPCR SYBR Green Mix (Thermo Fisher Scientific) and run on an MJ research
115 thermocycler with a Chromo4 Continuous Fluorescence Detection System (MJ Research)
116 in the following sequence: 95°C for 15 minutes, followed by 40 cycles of denaturation at
117 95°C for 15 seconds, annealing at 60°C for 30 seconds and extension at 72°C for 30
118 seconds. The sequences of primers are listed in Table S1. The relative concentration of
119 each gene was normalized to β -*ACTIN* and analysed using Q-Gene software package
120 (Simon 2003).

121 **Analysis of metabolic activity**

122 Media, collected from human ES cells 96 or 24 hours after addition of FCS or
123 Knockout™ SR and 24 hours after the culture medium was renewed, were snap-frozen in
124 liquid nitrogen and stored at -80°C. Media only controls comprised media that had been
125 incubated for 24 hours at 37°C in a well pre-coated with Matrigel™. Nutrient
126 consumption and metabolite production rates, expressed as fmol/cell/hour, were
127 calculated using the following formula: Consumption or production rate = $C_0 - C_1 / \#$ of
128 cells X # of hours where C_0 is the nutrient or metabolite concentration in control media
129 and C_1 is the nutrient or metabolite concentration in the experimental media. Cell refers
130 to the final cell number in each well. Final cell number in mTeSR1 + serum and mTeSR1
131 + KOSR was adjusted to reflect the cell loss seen in these conditions, estimated to be a
132 total of 11% over a 24 hour period.

133 *Measurement of carbohydrate consumption and production*

134 Glucose concentration in the media was estimated using an enzymatic assay linked to
135 NADPH production. One μ L of medium, previously diluted 1:10 in water, was added to

136 10 μL of glucose reagent (3.7 mM $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.6 mM NADP^+ , 0.5 mM ATP, 0.5 mM
137 dithiothreitol, 12 U hexokinase/mL, and 6 U G6PDH/mL in EPPS buffer with pH 8.0)
138 (Gardner and Leese 1990). Similarly, lactate concentration in the media was estimated
139 using an enzymatic assay linked to NADH production. Two μL of medium, previously
140 diluted 1:10 with water, were added to 10 μL of lactate reagent (4.76 mM NAD^+ , 100 U
141 LDH/mL, and 2.6 mM EDTA in glycine-hydrazine buffer with pH 9.4) (Gardner and
142 Leese 1990). Fluorescence was measured using a Nanodrop 3300 Fluorospectrometer
143 (Thermo Fisher Scientific).

144 The percentage of glycolysis was calculated based on one mole of glucose yields two
145 moles of lactate (% of glycolysis = # of moles of lactate / (# of moles of glucose x 2)).

146 *Measurement of amino consumption and production with Liquid Chromatography-Mass*
147 *Spectrometry (LC-MS)*

148 The concentration of amino acids in the culture media was measured by LC-MS. All
149 materials used for derivatisation of amino acids in the media and amino acid standards
150 were from Sigma-Aldrich. To derivatise amino acids, 10 μL of medium, diluted 1:30 in
151 water, was added to 70 μL of borate buffer (200 mM, pH = 8.8), followed by the addition
152 of 20 μL of 6-aminoquinolyl-*N*-hydroxysuccinimidyl carbamate (AQC) solution (3 mg of
153 AQC dissolved in 1 mL of dry acetonitrile). Reactions were shaken at 55°C for 10
154 minutes before LC-MS analysis on an Agilent 6410 LC-ESI-QQQ equipped with an
155 Agilent 1200 Series LC system (Agilent Technologies). A Multiple Reaction Monitor
156 was developed for each individual amino acid. Conditions were capillary temperature
157 300°C, capillary voltage 4000V, and gas flow rate 10 L/minute. The concentration of
158 each amino acid was obtained in every sample.

159 *Determination of amino acid turnover:*

160 The measurement of turnover was adapted from the approach of Houghton et al.
161 (Houghton *et al.* 2002), and represents the sum, in fmol/cell/hour of amino acids
162 consumed or released into the culture medium. Total amino acid turnover was the sum of
163 amino acid change in fmol/cell/hour.

164 ***Immunofluorescence***

165 Human ES cells were cultured on Matrigel™-treated glass coverslips in mTeSR1 and
166 supplements as described in the text. Cells were washed with PBS and fixed with 4%
167 PFA. Fixed monolayers were made permeable with PBS/0.25% TritonX, blocked with
168 1% BSA or donkey serum. Antigens were detected with antibodies directed against
169 NANOG (R&D Systems) or phospho-histone H3 (Ser10) (Cell Signaling Technologies)
170 in combination with an Alexa-Fluor 488 conjugated anti-goat antibody (NANOG; Life
171 Technologies) or an Alexa-Fluor 568 conjugated anti-rabbit antibody (Phospho-Histone
172 H3 (Ser10); Life Technologies); DNA was detected with DAPI. Images were taken on an
173 Olympus BX50 microscope with an Olympus F-viewII digital camera (NANOG) or a
174 confocal microscope (Phospho-Histone H3 (Ser10)). Percentage of mitotic cells was
175 calculated as the percentage of DAPI nuclei positive for phospho-histone H3 (Ser10) in
176 randomly captured fields.

177 **Statistical analysis**

178 Gene expression and carbohydrate use were analysed by Student's two-tailed t-test.
179 Analysis of the variance in amino acid use in control samples was performed using
180 ANOVA. Analysis of amino acid use in experimental samples, in comparison with the
181 controls, was performed using the R statistical software package with in-house

182 customized scripts. A logarithm transformation was applied to all metabolite
183 concentration measurements to minimize heteroscedastic noise to ensure a Gaussian data
184 distribution prior to analysis. A two-tailed paired Student's t-test was used to calculate
185 significant differences between the means of metabolite concentration responses.
186 Manhattan Hierarchical Cluster Analysis was undertaken to confirm reproducibility of
187 sample replicates and to determine the relationships between metabolites based on a
188 measure of distance similarity. Pearson Correlation Analysis was conducted on the
189 logarithm transformed metabolite measurements to confirm relationships of metabolite
190 consumption. For all analyses, a *P*-value of less than 0.05 was considered statistically
191 significant.

192 **Results**

193 *Serum induces sporadic differentiation of human ES cells.*

194 The human ES cell line MEL2 (Australian Stem Cell Centre) was cultured in mTeSR1
195 for 72 hours followed by 96 hours in mTeSR1 supplemented with one of two foetal calf
196 sera at a concentration of 20%. The sera used in this experiment had been selected for use
197 with mouse ES cells and shown to elicit low levels of cell differentiation (Rathjen and
198 Rathjen 2003) (Dr Jeff Mann, Murdoch Childrens Research Institute, Parkville, Victoria;
199 unpublished). In mTeSR1, human ES cells grew in tightly-packed colonies with smooth
200 edges (Figure 1A)(Ludwig *et al.* 2006b). The addition of serum resulted in a loosening of
201 the cells at the edge of the colonies and formation of a border region comprising
202 fibroblast-like cells (Figure 1B). Comparable alterations in morphology were observed
203 with both sera tested (Figure 1B, C).

204 Expression levels of the pluripotent markers *OCT4* and *NANOG* in cells cultured in
205 serum remained high and similar to cells cultured in mTeSR1 alone, although a small but
206 consistent reduction in *NANOG* expression was observed with both sources of sera
207 (Figure 1D). This reflected the substantial pool of pluripotent cells in cultures, as shown
208 by immunocytochemistry (Figure 1E). Only cells at the edge of the colonies had reduced
209 *NANOG* protein levels, while the majority of the cells within the colonies remained
210 *NANOG* positive. Markers of differentiation, *BRACHYURY* and *GATA4*, were elevated in
211 cells cultured in serum. The fold increase of these markers was variable between
212 experimental repeats suggesting that the proportion of differentiated cells in populations
213 cultured in serum was unpredictable. The reduction in *NANOG* expression, expression of
214 differentiation markers and morphology changes, however, suggested a heterogeneous

215 population of cells in serum in which the frequency of differentiated cells was increased.
216 A similar heterogeneity has been seen in mouse ES cells cultured in serum-supplemented
217 medium when compared to those cultured in defined medium (Marks *et al.* 2012).
218 Differentiation of mouse ES cells in response to serum requires p38 MAPK activity (CY
219 and JR unpublished). P38 MAPK activity can be inhibited pharmacologically with
220 SB203580 (4-(4'-fluorophenyl)-2-(4'-methylsulfinylphenyl)-5-(4'-pyridyl)-imidazole),
221 which inhibits p38 α , p38 β and p38 β 2 homologues by competing for ATP binding pockets
222 (Cuenda *et al.* 1995). The expression of pluripotent and differentiated markers were
223 analysed in cells cultured in mTeSR1 + FCS and compared to expression in cells cultured
224 in mTeSR1 + FCS + SB203580. Expression of *OCT4* was significantly increased, and
225 *BRACHYURY* and *GATA4* significantly decreased, in cells cultured in mTeSR1 + serum
226 + SB203580 (Figure 1F). These data confirm an increase in differentiation in cells
227 cultured in serum and suggest a requirement for p38 MAPK in the process.

228 ***Serum induces alterations in the metabolic activity of human ES cells in culture.***

229 Carbohydrate use by human ES cells cultured in mTeSR1 was compared to that of cells
230 exposed to serum for 24 and 96 hours. The measured concentration of glucose and lactate
231 in mTeSR1 and mTeSR1 + serum can be found in Table S2. Cells cultured in serum
232 consumed more glucose and produced more lactate than controls (Table 1). Glucose
233 consumption approximately doubled with 96 hours of exposure to serum. Although more
234 glucose was being metabolised by cell cultures exposed to serum, the percentage of
235 glucose metabolised glycolytically in these cells was not altered when compared to cells
236 cultured in mTeSR1 (Table 1).

237 In the published formulation of mTeSR the medium includes amino acids in a range of
238 concentrations standard for tissue culture maintenance. Repeated measurement of mTeSR
239 confirmed the presence and the concentration of amino acids in the medium, and
240 provided confidence that the technology used could reliably measure amino acids within
241 medium samples (Figure S1). In mTeSR1 + serum the concentrations of alanine, glutamic
242 acid and glycine were significantly increased when compared to mTeSR (Table S3). The
243 concentration of amino acids in medium used for culturing human ES cells was
244 determined and compared to unused medium. Cells cultured in mTeSR1 or mTeSR1 +
245 serum produced alanine, glutamic acid, proline and ornithine (Figure 2A). The production
246 of glutamic acid was significantly higher from cells cultured in serum (Figure 2A).
247 Human ES cells consumed arginine, cysteine, glutamine, glycine, isoleucine, leucine,
248 lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine and γ -
249 aminobutyric acid (GABA) (Figure 2A). The addition of serum to the culture medium
250 significantly increased the consumption of the majority of these amino acids (Figure 2A).
251 Overall, the addition of serum increased the total turnover of amino acids by the cells 1.9-
252 fold to 106 fmol/cell/hour (Figure 2B), comprised of a 1.7-fold increase in amino acid
253 production and a 1.9-fold increase in amino acid consumption.

254 ***Differentiation of human ES cells in response to BMP4 does not alter the carbohydrate***
255 ***usage or amino acid metabolism.***

256 Metabolism in pluripotent cells and somatic cells differs, suggesting that the changes in
257 glucose use and amino acid turnover in serum could arise from differentiated cells in the
258 population. Alternatively, changes in metabolomic activity could result from serum-
259 induced changes in the activity of all cells. The differentiation of human ES cells was

260 induced by the addition of BMP4 to mTeSR1 for 4 days (Hughes *et al.* 2009) and
261 carbohydrate usage and amino acid metabolism were measured. Like serum, BMP4
262 induces expression of *Brachyury* and *Gata4* (Kobayashi *et al.* 2008; Hughes *et al.*
263 2009)(CY and JR unpublished) and is likely to result in a repertoire of cells that overlaps
264 those formed in serum.

265 As expected, the addition of BMP4 resulted in an overtly differentiated colony
266 morphology with each colony consisting of a small core of pluripotent, NANOG positive,
267 cells surrounded by cells of an overtly differentiated phenotype (Figure 3A,B and data
268 not shown). Previous analysis has demonstrated the decreased expression of *NANOG* and
269 increased expression of differentiation markers in human ES cells exposed to BMP4
270 (Hughes *et al.* 2009). The analysis of spent medium from these cultures did not show any
271 changes in the consumption of glucose, production of lactate or percentage glycolysis
272 when compared to cells cultured in mTeSR1 (Table 1). Similarly, the addition of BMP4
273 had little effect on production or consumption of the amino acids tested, with differences
274 detected only in consumption of tryptophan and production of glutamic acid and proline,
275 and no overall change in amino acid turnover (Figure 3C, D).

276 ***Knockout™ SR induces metabolic changes in human ES cells.***

277 Knock-out serum replacer (Knockout™ SR; Life Technologies) is commonly used as a
278 medium supplement for the growth and differentiation of human ES cells (Adewumi *et*
279 *al.* 2007). Knockout™ SR was added to mTeSR1 and the effects on human ES cell
280 growth and metabolism were measured. Addition of 20% Knockout™ SR to mTeSR1
281 resulted in minor alterations in colony morphology, with some fibroblast-like cells

282 appearing at the edge of the colonies (Figure 4A, B). The change in colony morphology
283 was, however, much reduced in comparison to cells exposed to serum or BMP4.
284 Similarly, gene expression analysis of these cells did not detect any reduction in *NANOG*
285 expression or increase in the expression of the differentiation markers (Figure 4C).

286 Carbohydrate use by cells exposed to Knockout™ SR for 96 hours was compared to use
287 by cells cultured in mTeSR1 (Table 1). Knockout™ SR increased the consumption of
288 glucose and production of the lactate by approximately 1.4 fold. These changes were not
289 accompanied by a change in the percentage of glucose metabolised glycolytically.

290 The measurement of amino acid concentrations in medium containing Knockout™ SR
291 showed several amino acids, isoleucine, phenylalanine, proline, serine, threonine,
292 tryptophan and valine, to be present at unusually high concentrations when compared to
293 mTeSR1 (Table S4). These concentrations were not, however, unexpected when the
294 preferred embodiment of the medium contained within the patent describing the
295 formulation of Knockout™ SR is considered (Price 1998). The profile of amino acids
296 produced and consumed from cells exposed to Knockout™ SR was significantly different
297 from that of cells cultured in mTeSR1, and from cells exposed to serum or BMP4. Cells
298 in Knockout™ SR produced glycine, isoleucine, phenylalanine, threonine, valine and
299 GABA (Figure 5A). In contrast, cells cultured in mTeSR, mTeSR + serum and mTeSR +
300 BMP4 consumed these amino acids. The production of alanine, glutamic acid, and
301 proline, and the consumption of lysine and serine, was significantly increased by the
302 addition of Knockout™ SR (Figure 5A). Overall turnover of amino acids by cells
303 cultured in Knockout™ SR was increased 1.9-fold, to 109 fmol/cell/hour (Figure 5B).
304 Although this value was similar to the increase in amino acid turnover seen from cells

305 cultured in serum, the changes in production and consumption contributing to this were
306 different, with a 4.6 fold increase in amino acid production and 12% reduction in amino
307 acids consumed.

308 ***Cell proliferation is not affected by the addition of serum or Knockout™ SR.***

309 The addition of serum or Knockout™ SR potentially alters the growth characteristics of
310 human ES cells and affects the requirement of these cells for nutrients. The proportion of
311 cells in mitosis, identified by staining for phospho-histone H3 (Ser10), in human ES cells
312 cultured in mTeSR1 or mTeSR1 supplemented with serum or Knockout™ SR was
313 measured. No significant difference in cell proliferation was detected (Table 2). The
314 addition of serum or Knockout™ SR, however, did reduce the number of cells in culture
315 by approximately 50% at the time of assay (Table 3).

316 Discussion

317 The establishment of human ES cells by Thomson and colleagues in 1998 has resulted in
318 a dramatic increase in publications analysing the genetics, epigenetics and differentiation
319 of these cell lines, including multiparticipant studies that compared these characteristics
320 across multiple human ES cell lines (Adewumi *et al.* 2007; Akopian *et al.* 2010; Amps *et*
321 *al.* 2011). In contrast, there has been relatively little investigation of the physiology of
322 these cells, even when the suitability of medium formulations for human ES cell culture
323 is being tested (Akopian *et al.* 2010). Cellular metabolism is fundamental to embryo
324 viability and cell function (Gardner 1998; Lane and Gardner 2005), and has been shown
325 to be adapted in cells as they acquire characteristics of cancer and disease (Fritz and Fajas
326 2010; Chang and Wei 2011). If the clinical and commercial potential of human ES cells
327 is to be realized, a greater understanding of metabolic activity and regulation of metabolic
328 processes during stem cell derivation and differentiation will need to be acquired and
329 media formulations that support an appropriate metabolic state developed. Physiological
330 markers of pluripotency will find future applications in the validation and accreditation of
331 existing and newly isolated human ES cell lines.

332 In this study mTeSR1 was chosen as a standard human ES cell culture system against
333 which to compare the effect of supplements and differentiation on metabolism. mTeSR1
334 supports the growth of human ES cells in the absence of a feeder layer that would
335 otherwise complicate analysis (Ludwig *et al.* 2006a; Akopian *et al.* 2010). mTeSR1 has
336 been disclosed, which allows experimental measurements to be compared with the
337 published formulation (Ludwig *et al.* 2006a). The medium is based on a widely used
338 medium, DMEM:F12 mix, and provides salts, nutrients and amino acids at concentrations

339 previously determined to be sufficient for the culture of mammalian cells in culture and
340 extensively used for the culture of mouse pluripotent cells and human ES cells. The
341 medium contains a high concentration (13.7 mM) of glucose as an energy source. After
342 24 hours of culture in wells containing near confluent cell colonies the medium contained
343 approximately one third of starting glucose, a final concentration of between 4 and 5 mM.
344 The osmolality of supplemented medium remained within the normal range (data not
345 shown). Medium supplementation will, however, have modified the composition of the
346 medium and altered the concentration of growth factors in the formulation. Adding 20%
347 F12 to mTeSR1 did not alter cell proliferation, cell viability, or induce signs of
348 differentiation (Figure S2; Table S5), suggesting that diluted mTeSR maintained human
349 ES cells over the time course of this experiment.

350 The addition of serum or Knockout™ SR did not alter the rate of ES cell division, a
351 surprising result given the well-established role of serum in stimulating cell proliferation
352 in culture (Shodell and Rubin 1970). The cell cycle of mouse (Stead *et al.* 2002) and
353 human (Kapinas *et al.* 2013) ES cells is rapid, characterized by truncated gap phases and
354 distinct in structure from the cell cycle of somatic cells. In mouse, Cdk2, cyclin A and
355 cyclin E kinases are active throughout the cell cycle and lack the cell cycle periodicity
356 that is seen in somatic cells (Stead *et al.* 2002). The inability of serum to stimulate
357 pluripotent cell proliferation is likely a consequence of the unique characteristics of the
358 pluripotent cell cycle structure. The addition of the supplements did alter cell viability
359 and resulted in fewer cells surviving the period of treatment when compared to the
360 controls.

361 ***Glucose uptake and energy use are increased by serum and Knockout™ SR***

362 In mTeSR medium human ES cells used glucose as an energy source, with an estimated
363 50% of the glucose metabolized to lactate through glycolysis. The high contribution of
364 glycolysis to the energy needs of human ES cells is consistent with previous reports
365 (Prigione *et al.* 2010; Varum *et al.* 2011; Zhang *et al.* 2011). The use of glycolysis when
366 cultured in high oxygen tension (20% O₂), known as aerobic glycolysis, is a feature
367 shared with cancer cells and other rapidly proliferating cells in culture, and may reflect
368 the continual proliferation, or self-renewal, of human ES cells (Warburg 1956; Morgan
369 and Faik 1981; Brand *et al.* 1988; Fox *et al.* 2005; Lopez-Lazaro 2008; Gardner and Wale
370 2013; Harvey *et al.* *In press*).

371 The addition of serum or Knockout™ SR increased the amount of glucose used by the
372 cells but did not appear to alter the percentage of the glucose metabolized to lactate,
373 indicating that these supplements increased the energy requirements of the cells.
374 Carbohydrate use by mouse ES cells has been shown to be sensitive to medium
375 composition, with increased glucose uptake from serum-containing medium when
376 compared to medium supplemented with Knockout™ SR (Fernandes *et al.* 2010b).
377 Increased glucose uptake in cells cultured in serum could result from a higher flux of
378 glucose in differentiated cells within the population or from increased glucose flux in
379 human ES cells. Increased glucose flux in cells cultured in Knockout™ SR cannot be
380 explained by differentiation, and increasing the proportion of differentiated cells in the
381 human ES cell population, by inducing differentiation with BMP4, did not affect
382 carbohydrate use. These data suggest that the effect of serum and serum replacement on
383 glucose uptake was a consequence of the effect of medium composition. It cannot be
384 excluded that this effect was driven, in part, by dilution of mTeSR1 with the supplements.

385 *Amino acid turnover by human ES cells increases in response to serum and*
386 *Knockout™ SR*

387 The analysis of amino acid turnover during culture was used as a second indicator of
388 metabolite flux in human ES cells. Cells cultured in serum-supplemented mTeSR1
389 exhibited a 1.9-fold increased turnover of amino acids when compared to cells cultured in
390 mTeSR1; this increase was a consequence of an approximately 1.9-fold increase in the
391 use and production of amino acids by the population. As with glucose consumption,
392 increased amino acid turnover could be a consequence of the increase in differentiated
393 cells within the population. The addition of BMP4 to mTeSR increased cell
394 differentiation but had little effect on the consumption or production of amino acids, with
395 amino acid turnover similar between cells cultured in mTeSR and BMP4 and mTeSR
396 alone and only minor variations in the turnover of tryptophan, glutamic acid and proline
397 observed.

398

399 Cells cultured in mTeSR + Knockout™ SR also showed a 1.9-fold increase in amino acid
400 turnover. Unlike the increased turnover in serum, which affected all amino acids to a
401 similar degree, the increased turnover in cells cultured in Knockout™ SR comprised a
402 prodigious 4.6-fold increase in amino production coupled with a modest 12% decrease in
403 amino acid consumption. These changes occur without any overt differentiation in the
404 population suggesting they arise from a direct effect of Knockout™ SR on the human ES
405 cell. Collectively, these data demonstrate that the interaction of serum and Knockout™
406 SR with human ES cells resulted in a considerable up regulation of amino acid turnover.

407 Although similar in scale, increases in turnover resulted from specific cell responses to
408 the medium composition.

409 ***Differentiation and metabolic change are not coincident.***

410 The metabolism of pluripotent cells and somatic cells are different, which suggests that
411 differentiation will be accompanied by changes in metabolic activity and metabolic
412 pathway use. The differentiation of mouse ES cells has been shown to change
413 carbohydrate use (Kondoh *et al.* 2007; Fernandes *et al.* 2010a), and the differentiation of
414 human ES cells in response to retinoic acid (RA) has been shown to decrease glycolysis
415 (Zhang *et al.* 2011). In contrast, inducing differentiation of human ES cells with BMP4 in
416 mTeSR1 did not change carbohydrate use or glycolytic flux. The timing and regulation
417 of the metabolic changes that accompany differentiation are largely unexplored but
418 changes in metabolism occurred gradually when human ES cells were differentiated with
419 RA (Zhang *et al.* 2011). The unchanged carbohydrate use in BMP4-treated human ES
420 cells after 4 days potentially reflects the gradual nature of change, but may also be
421 impacted by the cell population formed and the medium used. Amino acid turnover was
422 also largely unaffected by human ES cell differentiation. Measuring the intracellular
423 metabolites present in mouse ES cells as they differentiate has shown no change in amino
424 acid concentrations, with the exception of an increase in threonine, and few changes in
425 other metabolites that were measured (Wang *et al.* 2009). These data suggest that in the
426 early stages of pluripotent cell differentiation, as examined here, changes in metabolism
427 lag behind the loss of pluripotence.

428 *Changes in the turnover of individual amino acids can be used as indicators of*
429 *changes in cell metabolism*

430 Cells cultured in serum supplemented medium consumed significantly more glutamine
431 than those cultured in control medium or mTeSR medium supplemented with BMP4 or
432 Knockout™ SR. Several proliferating cell types, including cancer cells (DeBerardinis *et*
433 *al.* 2007), metabolise glutamine to α -ketoglutarate via the formation of glutamate
434 (glutaminolysis), a process that liberates ammonium. The increased glutamine
435 consumption by human ES cells cultured in serum is consistent with increased
436 glutaminolysis and potentially reflects an increased flux of glutamine metabolites through
437 the tricarboxylic acid cycle (TCA) cycle. The increased production of glutamic acid and
438 alanine from cells could be a defensive strategy to alleviate the toxicity of the ammonium
439 formed as a consequence of serum exposure (Morgan and Faik 1981; Weinberg and
440 Chandel 2009). Glutamine consumption was not increased in mTeSR + Knockout™ SR
441 or mTeSR + BMP4 suggesting that neither of these conditions induced increases in
442 glutaminolysis.

443 The maintenance of pluripotency, and stable glutamine consumption, by Knockout™ SR
444 is consistent with this supplement being more compatible with the physiological needs of
445 human ES cells than serum. The addition of Knockout™ SR to mTeSR, however,
446 significantly altered the concentration of specific amino acids in the medium, increasing
447 their concentration by as much as 30-fold, as is the case for proline (Table S4). The
448 inclusion of Knockout™ SR resulted in profound changes in the way that amino acids
449 were utilized by the cells. In general, amino acids with increased concentrations in
450 Knockout™ SR supplemented medium were produced by cells cultured in Knockout™

451 SR but consumed by cells cultured in control medium; this was seen for glycine,
452 histidine, isoleucine, phenylalanine, threonine, tryptophan and valine. This was the only
453 medium formulation analysed that elicited changes from the consumption to production
454 of amino acids by the cells. The consumption of serine and production of proline, in
455 contrast, did not change to production and consumption, respectively, despite these amino
456 acids being increased with the addition of Knockout™ SR to mTeSR. For both of these
457 amino acids, however, the magnitude of amino acid turnover was significantly increased.
458 Finally, significant changes were seen in the turnover of alanine, lysine and glutamic acid
459 by cells cultured in Knockout™ SR. The concentrations of these amino acids did not
460 differ between supplemented medium and the control.

461 The changes in amino acid production detected in cells cultured in Knockout™ SR
462 indicated that multiple biosynthetic pathways were affected , which suggests a model in
463 which a general control process, such as those mediated by mTOR or GCN2 (Bruhat *et*
464 *al.* 2000; Kim 2009; Sancak *et al.* 2010), regulated biosynthetic activation across a
465 number of pathways. Counter intuitively, cells may perceive an amino acid limitation in
466 medium in which amino acid concentrations are not balanced. Elevated concentrations of
467 one amino acid can compromise the ability of a cell surface transporter of amino acids to
468 function and limit uptake of other amino acids. For example, the level of L-proline in
469 Knockout™ SR-supplemented medium is sufficient to inhibit SNAT2 uptake of a number
470 of amino acids, including glycine, alanine, serine, cysteine, glutamic acid, asparagine,
471 histidine and methionine (Tan *et al.* 2011), and may limit transport of these amino acids
472 into the cell, starving the cell of required nutrients and activating the amino acid sensing
473 pathways. Transporter-mediated amino acid limitation has been shown to regulate mTOR

474 signaling and activate the GCN2 pathway *in vivo* (Broer *et al.* 2011; Pinilla *et al.* 2011).
475 Activation of the amino acid sensing pathways, and downstream regulation of
476 biosynthetic pathways, could explain the changes in amino acids production in cells
477 cultured in Knockout™ SR. Although these changes to biosynthesis do not appear to alter
478 the pluripotency of the cells, it is likely changes of this magnitude will impact on other
479 aspects of cell function, including an increase in energy requirements. More analysis will
480 be required before the impact of Knockout™ SR on amino acid biosynthesis in human
481 ES cells can be understood but these data question the suitability of Knockout™ SR in its
482 current formulation for human ES cells culture.

483 Amino acids can be used by cells for biosynthesis, energy production and as signaling
484 molecules. Recently, a role for proline as a signaling molecule in pluripotent cell
485 differentiation in culture has been described (Washington *et al.* 2010; Tan *et al.* 2011).
486 Human ES cells cultured in mTeSR produced proline and production by cells cultured in
487 mTeSR + serum and mTeSR + Knockout™ SR was significantly increased; in
488 Knockout™ SR proline production was increased approximately 10-fold. Proline
489 production was significantly reduced with BMP4-induced differentiation suggesting that
490 the production of proline is a feature of the pluripotent cells. The elevated concentrations
491 of proline within the medium, either as a consequence of the elevated production of
492 proline by the cells or the addition of proline to the medium, could potentially alter the
493 pluripotent cell state or affect the stability of human ES cells in culture (Pera and Tam
494 2010; Washington *et al.* 2010; Tan *et al.* 2011).

495 The maintenance of high levels of pluripotency and inhibition of differentiation are the
496 key indicators that have been used to date to drive the development of culture conditions

497 for human ES cells. Although important these indicators do not reflect the physiology of
498 the cells; it is clear that the interaction of human ES cells with the medium can induce
499 significant alterations in carbohydrate use and amino acid turnover without necessarily
500 impacting on pluripotency. Addition of the supplements also affected cell growth, with
501 no change in the proliferation rate but significant cell loss from the populations during the
502 assay potentially reflecting a reduction in cell viability as a result of cell stress. The effect
503 of altered physiology on human ES cells and their differentiated derivatives is not known
504 but a wealth of studies of the early embryo suggest that the impact of sub-optimal culture
505 conditions and altered metabolism can be far reaching and affect long-term development
506 outcomes, potentially through interaction with the epigenome (Donohoe and Bultman
507 2012). The work reported here provides baseline measurements of carbohydrate use and
508 amino acid turnover in human ES cells cultured without feeders and in a fully described,
509 serum-free medium and establishes a model system that can be used to assess the effects
510 of environmental modulation on human ES cell metabolism, signaling pathway activity,
511 transcriptome and epigenome. Further studies are underway to characterise the fluxome
512 of human ES cells under these conditions, extending the observations reported here to a
513 more comprehensive range of metabolic pathways and processes.

514 Like serum, oxygen has been negatively associated with embryo metabolism and
515 outcome (Wale and Gardner 2012). There is a growing literature describing the effects of
516 ambient and reduced oxygen tensions on embryonic stem cells in culture. A number of
517 reports have shown increased pluripotency marker expression (Prasad *et al.* 2009;
518 Forristal *et al.* 2010), improved chromosomal stability (Forsyth *et al.* 2006), decreased
519 differentiation (Ezashi *et al.* 2005; Prasad *et al.* 2009; Zachar *et al.* 2010), increased

520 glycolysis (Kondoh *et al.* 2007), altered oxygen uptake rates (Abaci *et al.* 2010),
521 enhanced derivation of mouse (Gibbons *et al.* 2006) and human (Peura *et al.* 2007) ES
522 cells, and improved generation of iPS cells from mouse embryonic fibroblasts (Yoshida
523 *et al.* 2009) in lower oxygen tensions. There are, however, reports that have failed to
524 demonstrate significant differences between cells cultured in ambient and reduced
525 oxygen tensions (Ezashi *et al.* 2005; Forsyth *et al.* 2006; Prasad *et al.* 2009; Zachar *et al.*
526 2010). Comparison of these studies is hampered by the lack of consistency in other
527 components of the culture system, which could mask or accentuate the potentially subtle
528 effects elicited by oxygen, and the variable use of metabolic indicators, some of which
529 may be insensitive to oxygen tension. To achieve medium optimization we envisage that
530 the analysis of individual components of the culture environment, like amino acid
531 concentrations, protein supplements and oxygen tension, will need to be followed by
532 multifactorial and high-throughput approaches assessing combinations of selected
533 conditions and a range of sensitive and robust metabolic markers.

534

535 Acknowledgements

536 The authors would like to thank Dr. John Sheedy (University of Melbourne) for
537 assistance with the data analysis, Ms. Natasha Dodge, Ms. Mai Truong and Ms. Jackie
538 Yu for technical assistance and Dr. Jeff Mann for the ES cell-tested serum. This work
539 was supported by a Linkage grant from the Australian Research Council and Molecular
540 Biometrics Pty. Ltd. (Conneticut, USA).

541

542 **References**

- 543 Abaci, H.E., Truitt, R., Luong, E., Drazer, G., and Gerecht, S. (2010) Adaptation to
 544 oxygen deprivation in cultures of human pluripotent stem cells, endothelial progenitor
 545 cells, and umbilical vein endothelial cells. *Am J Physiol Cell Physiol* **298**(6), C1527-37
 546
- 547 Adewumi, O., Aflatoonian, B., Ahrlund-Richter, L., Amit, M., Andrews, P.W., Beighton,
 548 G., Bello, P.A., Benvenisty, N., Berry, L.S., Bevan, S., Blum, B., Brooking, J., Chen,
 549 K.G., Choo, A.B., Churchill, G.A., Corbel, M., Damjanov, I., Draper, J.S., Dvorak, P.,
 550 Emanuelsson, K., Fleck, R.A., Ford, A., Gertow, K., Gertsenstein, M., Gokhale, P.J.,
 551 Hamilton, R.S., Hampl, A., Healy, L.E., Hovatta, O., Hyllner, J., Imreh, M.P., Itskovitz-
 552 Eldor, J., Jackson, J., Johnson, J.L., Jones, M., Kee, K., King, B.L., Knowles, B.B., Lako,
 553 M., Lebrin, F., Mallon, B.S., Manning, D., Mayshar, Y., McKay, R.D., Michalska, A.E.,
 554 Mikkola, M., Mileikovsky, M., Minger, S.L., Moore, H.D., Mummery, C.L., Nagy, A.,
 555 Nakatsuji, N., O'Brien, C.M., Oh, S.K., Olsson, C., Otonkoski, T., Park, K.Y., Passier, R.,
 556 Patel, H., Patel, M., Pedersen, R., Pera, M.F., Piekarczyk, M.S., Pera, R.A., Reubinoff,
 557 B.E., Robins, A.J., Rossant, J., Rugg-Gunn, P., Schulz, T.C., Semb, H., Sherrer, E.S.,
 558 Siemen, H., Stacey, G.N., Stojkovic, M., Suemori, H., Szatkiewicz, J., Turetsky, T.,
 559 Tuuri, T., van den Brink, S., Vintersten, K., Vuoristo, S., Ward, D., Weaver, T.A.,
 560 Young, L.A., and Zhang, W. (2007) Characterization of human embryonic stem cell lines
 561 by the International Stem Cell Initiative. *Nat Biotechnol* **25**(7), 803-16
 562
- 563 Akopian, V., Andrews, P.W., Beil, S., Benvenisty, N., Brehm, J., Christie, M., Ford, A.,
 564 Fox, V., Gokhale, P.J., Healy, L., Holm, F., Hovatta, O., Knowles, B.B., Ludwig, T.E.,
 565 McKay, R.D., Miyazaki, T., Nakatsuji, N., Oh, S.K., Pera, M.F., Rossant, J., Stacey,
 566 G.N., and Suemori, H. (2010) Comparison of defined culture systems for feeder cell free
 567 propagation of human embryonic stem cells. *In Vitro Cell Dev Biol Anim* **46**(3-4), 247-58
 568
- 569 Amps, K., Andrews, P.W., Anyfantis, G., Armstrong, L., Avery, S., Baharvand, H.,
 570 Baker, J., Baker, D., Munoz, M.B., Beil, S., Benvenisty, N., Ben-Yosef, D., Biancotti,
 571 J.C., Bosman, A., Brena, R.M., Brison, D., Caisander, G., Camarasa, M.V., Chen, J.,
 572 Chiao, E., Choi, Y.M., Choo, A.B., Collins, D., Colman, A., Crook, J.M., Daley, G.Q.,
 573 Dalton, A., De Sousa, P.A., Denning, C., Downie, J., Dvorak, P., Montgomery, K.D.,
 574 Feki, A., Ford, A., Fox, V., Fraga, A.M., Frumkin, T., Ge, L., Gokhale, P.J., Golan-Lev,
 575 T., Gourabi, H., Gropp, M., Lu, G., Hampl, A., Harron, K., Healy, L., Herath, W., Holm,
 576 F., Hovatta, O., Hyllner, J., Inamdar, M.S., Irwanto, A.K., Ishii, T., Jaconi, M., Jin, Y.,
 577 Kimber, S., Kiselev, S., Knowles, B.B., Kopper, O., Kukhareno, V., Kuliev, A.,
 578 Lagarkova, M.A., Laird, P.W., Lako, M., Laslett, A.L., Lavon, N., Lee, D.R., Lee, J.E.,
 579 Li, C., Lim, L.S., Ludwig, T.E., Ma, Y., Maltby, E., Mateizel, I., Mayshar, Y.,
 580 Mileikovsky, M., Minger, S.L., Miyazaki, T., Moon, S.Y., Moore, H., Mummery, C.,
 581 Nagy, A., Nakatsuji, N., Narwani, K., Oh, S.K., Olson, C., Otonkoski, T., Pan, F., Park,
 582 I.H., Pells, S., Pera, M.F., Pereira, L.V., Qi, O., Raj, G.S., Reubinoff, B., Robins, A.,
 583 Robson, P., Rossant, J., Salekdeh, G.H., Schulz, T.C., Sermon, K., Sheik Mohamed, J.,
 584 Shen, H., Sherrer, E., Sidhu, K., Sivarajah, S., Skottman, H., Spits, C., Stacey, G.N.,

- 585 Strehl, R., Strelchenko, N., Suemori, H., Sun, B., Suuronen, R., Takahashi, K., Tuuri, T.,
586 Venu, P., Verlinsky, Y., Ward-van Oostwaard, D., Weisenberger, D.J., Wu, Y.,
587 Yamanaka, S., Young, L., and Zhou, Q. (2011) Screening ethnically diverse human
588 embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth
589 advantage. *Nat Biotechnol* **29**(12), 1132-44
590
- 591 Brand, K., Aichinger, S., Forster, S., Kupper, S., Neumann, B., Nurnberg, W., and
592 Ohrisch, G. (1988) Cell-cycle-related metabolic and enzymatic events in proliferating rat
593 thymocytes. *Eur J Biochem* **172**(3), 695-702
594
- 595 Brison, D.R., Houghton, F.D., Falconer, D., Roberts, S.A., Hawkhead, J., Humpherson,
596 P.G., Lieberman, B.A., and Leese, H.J. (2004) Identification of viable embryos in IVF by
597 non-invasive measurement of amino acid turnover. *Hum Reprod* **19**(10), 2319-24
598
- 599 Broer, A., Juelich, T., Vanslambrouck, J.M., Tietze, N., Solomon, P.S., Holst, J., Bailey,
600 C.G., Rasko, J.E., and Broer, S. (2011) Impaired nutrient signaling and body weight
601 control in a Na⁺ neutral amino acid cotransporter (Slc6a19)-deficient mouse. *J Biol Chem*
602 **286**(30), 26638-51
603
- 604 Bruhat, A., Jousse, C., Carraro, V., Reimold, A.M., Ferrara, M., and Fafournoux, P.
605 (2000) Amino acids control mammalian gene transcription: activating transcription factor
606 2 is essential for the amino acid responsiveness of the CHOP promoter. *Mol Cell Biol*
607 **20**(19), 7192-204
608
- 609 Chang, X., and Wei, C. (2011) Glycolysis and rheumatoid arthritis. *Int J Rheum Dis*
610 **14**(3), 217-22
611
- 612 Cuenda, A., Rouse, J., Doza, Y., Meier, R., Cohen, P., Gallagher, T., Young, P., and Lee,
613 J. (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is
614 stimulated by cellular stresses and interleukin-1. *FEBS letters* **364**(2), 229-233
615
- 616 DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., and
617 Thompson, C.B. (2007) Beyond aerobic glycolysis: transformed cells can engage in
618 glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis.
619 *Proc Natl Acad Sci U S A* **104**(49), 19345-50
620
- 621 Donohoe, D.R., and Bultman, S.J. (2012) Metaboloepigenetics: interrelationships
622 between energy metabolism and epigenetic control of gene expression. *J Cell Physiol*
623 **227**(9), 3169-77
624
- 625 Ezashi, T., Das, P., and Roberts, R.M. (2005) Low O₂ tensions and the prevention of
626 differentiation of hES cells. *Proc Natl Acad Sci U S A* **102**(13), 4783-8
627
- 628 Fernandes, T.G., Diogo, M.M., Fernandes-Platzgummer, A., da Silva, C.L., and Cabral,
629 J.M. (2010a) Different stages of pluripotency determine distinct patterns of proliferation,

- 630 metabolism, and lineage commitment of embryonic stem cells under hypoxia. *Stem Cell*
631 *Res* **5**(1), 76-89
632
- 633 Fernandes, T.G., Fernandes-Platzgummer, A.M., da Silva, C.L., Diogo, M.M., and
634 Cabral, J.M. (2010b) Kinetic and metabolic analysis of mouse embryonic stem cell
635 expansion under serum-free conditions. *Biotechnol Lett* **32**(1), 171-9
636
- 637 Forristal, C.E., Wright, K.L., Hanley, N.A., Oreffo, R.O., and Houghton, F.D. (2010)
638 Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic
639 stem cells cultured at reduced oxygen tensions. *Reproduction* **139**(1), 85-97
640
- 641 Forsyth, N.R., Musio, A., Vezzoni, P., Simpson, A.H., Noble, B.S., and McWhir, J.
642 (2006) Physiologic oxygen enhances human embryonic stem cell clonal recovery and
643 reduces chromosomal abnormalities. *Cloning Stem Cells* **8**(1), 16-23
644
- 645 Fox, C.J., Hammerman, P.S., and Thompson, C.B. (2005) Fuel feeds function: energy
646 metabolism and the T-cell response. *Nat Rev Immunol* **5**(11), 844-52
647
- 648 Fritz, V., and Fajas, L. (2010) Metabolism and proliferation share common regulatory
649 pathways in cancer cells. *Oncogene* **29**(31), 4369-77
650
- 651 Gardner, D.K. (1998) Changes in requirements and utilization of nutrients during
652 mammalian preimplantation embryo development and their significance in embryo
653 culture. *Theriogenology* **49**(1), 83-102
654
- 655 Gardner, D.K. (2011) Analysis of embryo metabolism and the metabolome to identify the
656 most viable embryo within a cohort. In 'Human Assisted Reproductive Technology.' (Eds.
657 DK Gardner, BRMB Rizk and T Falcone) pp. 301-312. (Cambridge University Press:
658 New York)
659
- 660 Gardner, D.K., and Leese, H.J. (1990) Concentrations of nutrients in mouse oviduct fluid
661 and their effects on embryo development and metabolism in vitro. *J Reprod Fertil* **88**(1),
662 361-8
663
- 664 Gardner, D.K., and Wale, P.L. (2013) Analysis of metabolism to select viable human
665 embryos. *Fertil Steril* **In Press**
666
- 667 Gardner, D.K., Wale, P.L., Collins, R., and Lane, M. (2011) Glucose consumption of
668 single post-compaction human embryos is predictive of embryo sex and live birth
669 outcome. *Hum Reprod* **26**(8), 1981-6
670
- 671 Gibbons, J., Hewitt, E., and Gardner, D.K. (2006) Effects of oxygen tension on the
672 establishment and lactate dehydrogenase activity of murine embryonic stem cells.
673 *Cloning Stem Cells* **8**(2), 117-22
674

- 675 Harvey, A.J., Rathjen, J., and Gardner, D.K. (*In press*) The metabolic framework of
676 pluripotent stem cells and potential mechanisms of regulation. In 'Stem Cells in
677 Reproductive Medicine. Vol. 3rd edition.' (Eds. C Simon, A Pellicer and R Reijo-Pera).
678 (Cambridge University Press: Cambridge)
679
- 680 Houghton, F.D., Hawkhead, J.A., Humpherson, P.G., Hogg, J.E., Balen, A.H.,
681 Rutherford, A.J., and Leese, H.J. (2002) Non-invasive amino acid turnover predicts
682 human embryo developmental capacity. *Hum Reprod* **17**(4), 999-1005
683
- 684 Hughes, J.N., Dodge, N., Rathjen, P.D., and Rathjen, J. (2009) A novel role for gamma-
685 secretase in the formation of primitive streak-like intermediates from ES cells in culture.
686 *Stem Cells* **27**(12), 2941-51
687
- 688 Kapinas, K., Grandy, R., Ghule, P., Medina, R., Becker, K., Pardee, A., Zaidi, S.K., Lian,
689 J., Stein, J., van Wijnen, A., and Stein, G. (2013) The abbreviated pluripotent cell cycle. *J*
690 *Cell Physiol* **228**(1), 9-20
691
- 692 Khosla, S., Dean, W., Reik, W., and Feil, R. (2001) Culture of preimplantation embryos
693 and its long-term effects on gene expression and phenotype. *Hum Reprod Update* **7**(4),
694 419-27
695
- 696 Kim, E. (2009) Mechanisms of amino acid sensing in mTOR signaling pathway. *Nutr Res*
697 *Pract* **3**(1), 64-71
698
- 699 Kobayashi, M., Takada, T., Takahashi, K., Noda, Y., and Torii, R. (2008) BMP4 induces
700 primitive endoderm but not trophectoderm in monkey embryonic stem cells. *Cloning*
701 *Stem Cells* **10**(4), 495-502
702
- 703 Kondoh, H., Leonart, M.E., Nakashima, Y., Yokode, M., Tanaka, M., Bernard, D., Gil,
704 J., and Beach, D. (2007) A high glycolytic flux supports the proliferative potential of
705 murine embryonic stem cells. *Antioxid Redox Signal* **9**(3), 293-9
706
- 707 Lane, M., and Gardner, D.K. (1996) Selection of viable mouse blastocysts prior to
708 transfer using a metabolic criterion. *Hum Reprod* **11**(9), 1975-8
709
- 710 Lane, M., and Gardner, D.K. (2005) Understanding cellular disruptions during early
711 embryo development that perturb viability and fetal development. *Reprod Fertil Dev*
712 **17**(3), 371-8
713
- 714 Lopez-Lazaro, M. (2008) The warburg effect: why and how do cancer cells activate
715 glycolysis in the presence of oxygen? *Anticancer Agents Med Chem* **8**(3), 305-12
716
- 717 Ludwig, T.E., Bergendahl, V., Levenstein, M.E., Yu, J., Probasco, M.D., and Thomson,
718 J.A. (2006a) Feeder-independent culture of human embryonic stem cells. *Nat Methods*
719 **3**(8), 637-46
720

- 721 Ludwig, T.E., Levenstein, M.E., Jones, J.M., Berggren, W.T., Mitchen, E.R., Frane, J.L.,
722 Crandall, L.J., Daigh, C.A., Conard, K.R., Piekarczyk, M.S., Llanas, R.A., and Thomson,
723 J.A. (2006b) Derivation of human embryonic stem cells in defined conditions. *Nat*
724 *Biotechnol* **24**(2), 185-7
725
- 726 Marks, H., Kalkan, T., Menafrá, R., Denissov, S., Jones, K., Hofemeister, H., Nichols, J.,
727 Kranz, A., Stewart, A.F., Smith, A., and Stunnenberg, H.G. (2012) The transcriptional
728 and epigenomic foundations of ground state pluripotency. *Cell* **149**(3), 590-604
729
- 730 Morgan, M.J., and Faik, P. (1981) Carbohydrate metabolism in cultured animal cells.
731 *Biosci Rep* **1**(9), 669-86
732
- 733 Oddens, B.a.L., B. (2006) 'A decade of success in ART.' (Elsevier: Amsterdam)
734
- 735 Pera, M.F., and Tam, P.P. (2010) Extrinsic regulation of pluripotent stem cells. *Nature*
736 **465**(7299), 713-20
737
- 738 Peura, T.T., Bosman, A., and Stojanov, T. (2007) Derivation of human embryonic stem
739 cell lines. *Theriogenology* **67**(1), 32-42
740
- 741 Pinilla, J., Aledo, J.C., Cwiklinski, E., Hyde, R., Taylor, P.M., and Hundal, H.S. (2011)
742 SNAT2 transceptor signalling via mTOR: a role in cell growth and proliferation? *Front*
743 *Biosci (Elite Ed)* **3**, 1289-99
744
- 745 Prasad, S.M., Czepiel, M., Cetinkaya, C., Smigielska, K., Weli, S.C., Lysdahl, H.,
746 Gabrielsen, A., Petersen, K., Ehlers, N., Fink, T., Minger, S.L., and Zachar, V. (2009)
747 Continuous hypoxic culturing maintains activation of Notch and allows long-term
748 propagation of human embryonic stem cells without spontaneous differentiation. *Cell*
749 *Prolif* **42**(1), 63-74
750
- 751 Price, P.J., Goldsborough, M.D., Tilkens, M.L. International Patent Application WO
752 98/30679. (1998) Embryonic stem cell serum
753 replacement. *International Patent Application WO 98/30679*.
754
- 755 Prigione, A., Fauler, B., Lurz, R., Lehrach, H., and Adjaye, J. (2010) The senescence-
756 related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent
757 stem cells. *Stem Cells* **28**(4), 721-33
758
- 759 Rathjen, J., and Rathjen, P.D. (2003) Lineage specific differentiation of mouse ES cells:
760 formation and differentiation of early primitive ectoderm-like (EPL) cells. *Methods*
761 *Enzymol* **365**, 3-25
762
- 763 Reubinoff, B.E., Pera, M.F., Fong, C.Y., Trounson, A., and Bongso, A. (2000)
764 Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. *Nat*
765 *Biotechnol* **18**(4), 399-404
766

- 767 Sakkas, D., and Gardner, D.K. (2005) Noninvasive methods to assess embryo quality.
768 *Curr Opin Obstet Gynecol* **17**(3), 283-8
769
- 770 Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A.L., Nada, S., and Sabatini, D.M.
771 (2010) Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is
772 necessary for its activation by amino acids. *Cell* **141**(2), 290-303
773
- 774 Shodell, M., and Rubin, H. (1970) Studies on the nature of serum stimulation of
775 proliferation in cell culture. *In Vitro* **6**(1), 66-74
776
- 777 Simon, P. (2003) Q-Gene: processing quantitative real-time RT-PCR data. *Bioinformatics*
778 **19**(11), 1439-40
779
- 780 Stead, E., White, J., Faast, R., Conn, S., Goldstone, S., Rathjen, J., Dhingra, U., Rathjen,
781 P., Walker, D., and Dalton, S. (2002) Pluripotent cell division cycles are driven by
782 ectopic Cdk2, cyclin A/E and E2F activities. *Oncogene* **21**(54), 8320-33
783
- 784 Tan, B.S., Lonic, A., Morris, M.B., Rathjen, P.D., and Rathjen, J. (2011) The amino acid
785 transporter SNAT2 mediates L-proline-induced differentiation of ES cells. *Am J Physiol*
786 *Cell Physiol* **300**(6), C1270-9
787
- 788 Thompson, J.G., Gardner, D.K., Pugh, P.A., McMillan, W.H., and Tervit, H.R. (1995)
789 Lamb birth weight is affected by culture system utilized during in vitro pre-elongation
790 development of ovine embryos. *Biol Reprod* **53**(6), 1385-91
791
- 792 Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J.,
793 Marshall, V.S., and Jones, J.M. (1998) Embryonic stem cell lines derived from human
794 blastocysts. *Science* **282**(5391), 1145-7
795
- 796 Varum, S., Rodrigues, A.S., Moura, M.B., Momcilovic, O., Easley, C.A.t., Ramalho-
797 Santos, J., Van Houten, B., and Schatten, G. (2011) Energy metabolism in human
798 pluripotent stem cells and their differentiated counterparts. *PLoS One* **6**(6), e20914
799
- 800 Wale, P.L., and Gardner, D.K. (2012) Oxygen regulates amino acid turnover and
801 carbohydrate uptake during the preimplantation period of mouse embryo development.
802 *Biol Reprod* **87**(1), 24, 1-8
803
- 804 Wang, J., Alexander, P., Wu, L., Hammer, R., Cleaver, O., and McKnight, S.L. (2009)
805 Dependence of mouse embryonic stem cells on threonine catabolism. *Science* **325**(5939),
806 435-9
807
- 808 Warburg, O. (1956) On the origin of cancer cells. *Science* **123**(3191), 309-14
809
- 810 Washington, J.M., Rathjen, J., Felquer, F., Lonic, A., Bettess, M.D., Hamra, N.,
811 Semendric, L., Tan, B.S., Lake, J.A., Keough, R.A., Morris, M.B., and Rathjen, P.D.

- 812 (2010) L-Proline Induces Differentiation of Es Cells: A Novel Role for an Amino Acid in
813 the Regulation of Pluripotent Cells in Culture. *Am J Physiol Cell Physiol*
814
- 815 Weinberg, F., and Chandel, N.S. (2009) Mitochondrial Metabolism and Cancer. *Hypoxia*
816 *and Consequences from Molecule to Malady* **1177**, 66-73
817
- 818 Yoshida, Y., Takahashi, K., Okita, K., Ichisaka, T., and Yamanaka, S. (2009) Hypoxia
819 enhances the generation of induced pluripotent stem cells. *Cell Stem Cell* **5**(3), 237-41
820
- 821 Zachar, V., Prasad, S.M., Weli, S.C., Gabrielsen, A., Petersen, K., Petersen, M.B., and
822 Fink, T. (2010) The effect of human embryonic stem cells (hESCs) long-term normoxic
823 and hypoxic cultures on the maintenance of pluripotency. *In Vitro Cell Dev Biol Anim*
824 **46**(3-4), 276-83
825
- 826 Zhang, J., Khvorostov, I., Hong, J.S., Oktay, Y., Vergnes, L., Nuebel, E., Wahjudi, P.N.,
827 Setoguchi, K., Wang, G., Do, A., Jung, H.J., McCaffery, J.M., Kurland, I.J., Reue, K.,
828 Lee, W.N., Koehler, C.M., and Teitell, M.A. (2011) UCP2 regulates energy metabolism
829 and differentiation potential of human pluripotent stem cells. *EMBO J* **30**(24), 4860-73
830
831
832

833

834 **Figure Legends**

835 **Figure 1: Serum induces differentiation from human ES cells. A-C.** MEL2 human ES
836 cells were cultured in mTeSR1 for 7 days (A) or mTeSR1 for 72 hours followed by
837 mTeSR1 with 20% added FCS for 96 hours (B, C). Serum was from Life Technologies
838 (B) or Hyclone (C). Size bars represent 500 μ m. **D.** Human ES cells were collected on day
839 7 and analysed for the expression of *OCT4*, *NANOG*, *GATA4* and *BRACHYURY* by RT-
840 qPCR. n=8 independent repeats. Error bars represent SEM. Data was analysed using a
841 two-tailed Student's t-test * $p < 0.05$. **E.** Human ES cells exposed to Life Technologies
842 FCS for 96 hours were analysed by immunocytochemistry for the presence of NANOG.
843 Nuclei were detected by DAPI. Arrows highlight examples of cells that have lost
844 NANOG expression. **F.** Human ES cells on day 3 of culture were transferred to
845 mTeSR1+FCS+SB203580 (SB) and cultured for a further 4 days. Cells were collected
846 and analysed for the expression of *OCT4*, *NANOG*, *SOX2*, *GATA4* and *BRACHYURY* by
847 RT-qPCR. Gene expression was normalized to mTeSR1+FCS+DMSO controls. n=3
848 independent repeats. Error bars represent SEM. Data was analysed using a two-tailed
849 Student's t-test # $p < 0.01$.

850 **Figure 2: Exposure to serum changes the use of amino acids in human ES cell**
851 **cultures.** **A.** Spent medium from the final 24 hours of culture of human ES cells in
852 mTeSR1 for 7 days (\square), or mTeSR1 for 72 hours followed by mTeSR1 with 20% Life
853 Technologies FCS for 96 hours (\blacksquare), was analysed for the presence and concentration of
854 amino acids. Amino acid production (positive values) or consumption (negative values)
855 has been normalised to cell number and is expressed as fmol/cell/hour. n=8 independent

856 repeats. Error bars represent SEM. Data were analysed using a two-tailed Student's t-test,
857 * $p < 0.05$; ** $p < 0.01$. **B.** Total amino acid production, consumption and turnover by cells
858 cultured in medium supplemented with serum.

859 **Figure 3: Differentiation of human ES cells with BMP4 does not result in changes in**
860 **amino acid usage. A,B.** Human ES cells were cultured in mTeSR1 for 5 days (A) or
861 mTeSR1 for 72 hours followed by 48 hours in mTeSR1 with 30 ng/mL BMP4 (B). Size
862 bars represent 500 μ m. **C.** Human ES cells were cultured in mTeSR1 for 7 days or
863 mTeSR1 for 72 hours followed by 96 hours in mTeSR1 with 30 ng/mL BMP4. Spent
864 medium from the final 24 hours of culture was analysed for the presence and
865 concentration of amino acids. Amino acid production (positive values) or consumption
866 (negative values) has been normalised to cell number and is expressed as fmol/cell/hour.
867 $n=6$ independent repeats. Error bars represent SEM. Data were analysed statistically
868 using a two-tailed Student's t-test; * $p < 0.05$. **D.** Total amino acid production,
869 consumption and turnover by cells cultured in medium supplemented with BMP4.

870 **Figure 4: The addition of 20% Knockout™ SR does not induce detectable**
871 **differentiation in human ES cells cultures. A,B.** Human ES cells were cultured in
872 mTeSR1 for 7 days (A) or mTeSR1 for 72 hours followed by 96 hours in mTeSR1 with
873 20% Knockout™ SR (B). Size bars represent 500 μ m. **C.** Cells were collected on day 7
874 and analysed for the expression of *OCT4*, *NANOG*, *GATA4* and *BRACHYURY* by RT-
875 qPCR. $n=8$ independent repeats. Error bars represent SEM. Data was analysed using a
876 two-tailed Student's t-test; no differences were detected.

877 **Figure 5: Exposure to Knockout™ SR changes amino acid metabolism in human ES**
878 **cells. A.** Spent medium from the final 24 hours of culture of human ES cells in mTeSR1
879 for 7 days (□), or mTeSR1 for 72 hours followed by mTeSR1 with 20% Knockout™ SR
880 for 96 hours (■), was analysed for the presence and concentration of amino acids. Amino
881 acid production (positive values) or consumption (negative values) has been normalised
882 to cell number and is expressed as fmol/cell/hour. n=12 (6 independent repeats with
883 duplicate wells for each experiment). Error bars represent SEM. Data were analysed
884 using a two-tailed Student's t-test, *p<0.05; **p<0.01. **B.** Total amino acid production,
885 consumption and turnover by cells cultured in medium supplemented with Knockout™
886 SR.

| | Glucose consumption (fmol/cell/hour) | Lactate Production (fmol/cell/hour) | %Glycolysis |
|--|--|---|--------------------|
| mTeSR | 160 ± 9 | 162 ± 12 | 50.5 ± 2.1 |
| mTeSR + FCS^a; 24 hours^b | 181 ± 24 | 187 ± 24 | 52.3 ± 3.3 |
| mTeSR + FCS^a; 96 hours | 357 ± 38** | 359 ± 40** | 50.5 ± 3.4 |
| mTeSR | 162 ± 12 | 171 ± 14 | 53.7 ± 1.4 |
| mTeSR + BMP4^c; 96 hours | 163 ± 10 | 182 ± 14 | 55.1 ± 3.3 |
| mTeSR | 171 ± 20 | 179 ± 11 | 52.1 ± 1.6 |
| mTeSR + KOSR^d; 96 hours | 242 ± 16** | 251 ± 15** | 52.1 ± 2.5 |

Table 1. Carbohydrate use by human ES cells cultured in mTeSR1 with and without supplementation. ^a 20% FCS from Life Technologies. ^b All measurements were made on medium taken after the final 24 hours of culture; time in the conditions indicates the length of exposure of the cells to the supplement. ^cBMP4 at 30 ng/ml. ^d 20% KOSR from Life Technologies.

| | % cells in mitosis +/- s.e.m. | <i>p</i>-value |
|---------------------------------|--|-----------------------|
| mTeSR | 3.6 ± .3 | |
| mTeSR + FCS^a | 4.3 ± .5 | .26 |
| mTeSR + KOSR^b | 3.0 ± .5 | .27 |

Table 2: Proliferation of human ES cells, shown as the % of cells positive for phosphorylated histone H3.

^a20% FCS from Life Technologies. ^b20% Knockout Serum Replacer from Life Technologies. *P*-value determined by Student's t-test when compared to cells cultured in mTeSR. Analysis was of 20 fields from two independent replicates.

| | Average cell number | <i>p</i> -value | % mTeSR |
|---------------------------------|---|------------------------|----------------|
| mTeSR | $1.92 \times 10^6 \pm 1.43 \times 10^5$ | | |
| mTeSR + FCS^a | $9.60 \times 10^5 \pm 1.83 \times 10^5$ | 2.00×10^{-3} | 49.8 ± 8.1 |
| mTeSR | $2.09 \times 10^6 \pm 8.90 \times 10^4$ | | |
| mTeSR + KOSR^b | $1.24 \times 10^6 \pm 8.40 \times 10^4$ | 9.57×10^{-12} | 61.0 ± 2.5 |

Table 3: Cell numbers after 4 days of supplement addition. ^a 20% FCS from Life Technologies. ^b 20% Knockout Serum Replacer from Life Technologies. Statistical comparison of raw cell numbers was performed using a paired Student's t-test, and of cell numbers relative to mTeSR with an unpaired Student's t-test.






Figure 1




Figure 2_Rathjen et al.,





Figure 3_Rathjen et al.






Figure 4

A



B




Figure 5_Rathjen

| Gene | Forward primer 5'-3' | Reverse primer 5'-3' |
|------------------|---------------------------------|---------------------------------|
| <i>B-ACTIN</i> | CGCACCACTGGCATTGTC | TCCTCCTTGATGTCACGCAC |
| <i>BRACHYURY</i> | GTGCTGTCCCAGGTGGCTTACAGATG | CCTTAACAGCTCAACTCTAACTACTTG |
| <i>GATA4</i> | CTAGACCGTGGGTTTTGCAT | TGGGTTAAGTGCCCCTGTAG |
| <i>NANOG</i> | CAAAGGCAAACAACCCACTT | TCTGCTGGAGGCTGAGGT |
| <i>OCT4</i> | AGCGAACCAGTATCGAGAAC | TTACAGAACCACACTCGCAC |
| <i>SOX2</i> | ATGCACCGCTACGACGTGA | CTTTGCACCCCTCCCATTT |

Table S1: Primer sequences used for qPCR analysis of gene expression.

| | Expected glucose concentration (mM) | Measured glucose concentration (mM) | Expected lactate concentration (mM) | Measured lactate concentration (mM) |
|---------------------|--|--|--|--|
| mTeSR | 13.7 | 15.2 ± .4 | 0 | 0 |
| mTeSR + FCS | | 13.4 ± .5 | | 2.4 ± .1 |
| mTeSR + BMP4 | 13.7 | 14.5 ± .3 | 0 | 0 |
| mTeSR + KOSR | | 13.7 ± .4 | | 0 |

Table S2: Measured concentrations of glucose and lactate in control media.

| | mTeSR formulation (μM) | mTeSR (μM) | mTeSR + FCS (μM) |
|------------|--|--------------------------------------|--|
| Ala | 137 | 158 \pm 3.54 | 326 \pm 4.6** |
| Arg | 548 | 459 \pm 8.5 | 328 \pm 5.6 |
| Asn | 137 | 129 \pm 2.1 | 103 \pm 1.5 |
| Asp | 137 | 157 \pm 3.4 | 144 \pm 2.8 |
| Glu | 137 | 157 \pm 2.9 | 301 \pm 3.6** |
| Gln | 2940 | 2362 \pm 38.1 | 1973 \pm 38 |
| Gly | 294 | 269 \pm 7.9 | 336 \pm 10.7** |
| His | 118 | 151 \pm 1.9 | 145 \pm 2.5 |
| Ile | 326 | 318 \pm 6.1 | 291 \pm 3.5 |
| Leu | 354 | 352 \pm 7.1 | 333 \pm 3.8 |
| Lys | 391 | 358 \pm 5.5 | 331 \pm 3.2 |
| Met | 90.6 | 89 \pm 1.9 | 76 \pm 1.2 |
| Phe | 169 | 187 \pm 3.5 | 182 \pm 2.1 |
| Pro | 216 | 233 \pm 2.8 | 237 \pm 2.1 |
| Ser | 294 | 304 \pm 8.9 | 300 \pm 8.1 |
| Thr | 352 | 343 \pm 6.4 | 301 \pm 3.2 |
| Trp | 34.6 | 68 \pm 1.2 | 71 \pm 1.3 |
| Tyr | 168 | 174 \pm 3.1 | 160 \pm 1.7 |
| Val | 355 | 355 \pm 6.4 | 355 \pm 3.8 |

Table S3: Measured concentrations of amino acids in mTeSR and mTeSR supplemented with 20% Life Technologies FCS, compared to the expected concentrations from the published formulation of the medium¹⁸. ** p<0.01; significance was tested for those amino acids showing an increased concentration in serum containing medium.

| | mTeSR formulation (μM) | mTeSR (μM) | mTeSR + KOSR formulation (μM) | mTeSR + KOSR (μM) |
|------------|---|---|--|--|
| Ala | 137 | 144 \pm 2.5 | 109.6 | 123 \pm 4.9 |
| Arg | 548 | 581 \pm 4.9 | 438.4 | 463 \pm 16.1 |
| Asn | 137 | 142 \pm 2.2 | 109.6 | 113 \pm 2.7 |
| Asp | 137 | 139 \pm 8.8 | 109.6 | 106 \pm 4 |
| Glu | 137 | 138 \pm 6.2 | 109.6 | 105 \pm 6 |
| Gln | 2940 | 2614 \pm 29.5 | 2352 | 2065 \pm 46.5 |
| Gly | 294 | 296 \pm 4.5 | 1176.4 | 621 \pm 19.1 |
| His | 118 | 116 \pm 7.6 | 1667 | 925 \pm 36.3 |
| Ile | 326 | 332 \pm 6.4 | 6512 | 4957 \pm 118.8 |
| Leu | 354 | 358 \pm 6.8 | 283.2 | 369 \pm 9.4 |
| Lys | 391 | 393 \pm 10.7 | 312.8 | 308 \pm 8.3 |
| Met | 90.6 | 81.6 \pm 4.3 | 465.68 | 172 \pm 4.4 |
| Phe | 169 | 188 \pm 4.1 | 2847.2 | 2129 \pm 55.6 |
| Pro | 216 | 242 \pm 5.9 | 7111.2 | 6445 \pm 144.5 |
| Ser | 294 | 281 \pm 4.7 | 2290.6 | 1635 \pm 46.5 |
| Thr | 352 | 353 \pm 9 | 5038.2 | 3452 \pm 82 |
| Trp | 34.6 | 47 \pm 2.9 | 812 | 455 \pm 13 |
| Tyr | 168 | 226 \pm 4.9 | 752 | 225 \pm 4.9 |
| Val | 355 | 370 \pm 7.4 | 5450 | 3977 \pm 92.6 |

Table S4: Measured concentrations of amino acids in mTeSR and mTeSR supplemented with 20% Life Technologies KOSR, compared to the expected concentrations from the published formulation of mTeSR¹⁸ and mTeSR + KOSR. Expected concentrations for amino acids in KOSR were taken from the preferred embodiment of the supplement²⁰.

| | % cells in mitosis ± s.e.m. | <i>p</i>-value | Fluorescent intensity (relative units) ± s.e.m. | <i>p</i>-value |
|--------------------|--|-----------------------|--|-----------------------|
| mTeSR | 3.6 ± .3 | | 2.95 ± .3 | |
| mTeSR + F12 | 3.6 ± .3 | .86 | 2.76 ± .2 | .65 |

Table S5: Proliferation of human ES cells, shown as the % of cells positive for phosphorylated histone H3, in medium conditions used, and final live cell density, estimated by Alamar Blue staining, shown as fluorescent intensity. *P*-value determined by Student's *t*-test when compared to cells cultured in mTeSR. Analysis was of 20 fields from two independent replicates (proliferation rate) and 6 replicate wells (final live cell density).





Figure S2: Comparison of amino acid use in human ES cell cultures across experimental procedures.
 A. Spent medium from the final 24 hours of culture of human ES cells in mTeSR1 for 7 days was analysed for the presence and concentration of amino acids. Amino acid production or consumption was normalised to cell number and is expressed as fmol/cell/hour. n=8 (Control 1); n=6 (Control 2); n=12 (Control 3). Error bars represent SEM. Data were analysed using ANOVA, *p<0.05. B. Total amino acid production, consumption and turnover by cells cultured in mTeSR1.

Supplementary figure 1_Rathjen et al.



Supplementary Figure 2: Morphology of human ES cells cultured in mTeSR1 supplemented with 20% Hams F12 medium. Human ES cells were cultured for 3 days in mTeSR1 before being changed into mTeSR1 (A,C) or mTeSR1 supplemented with 20% Hams F12 (B,D) and maintained for a further 4 days. Images of colony morphology were captured in phase contrast at 4 x magnification (A,B) or with fluorescence microscopy after staining for DNA with DAPI (C,D; 20 x magnification). n=3; representative images are shown.

Supplementary figure 2_Rathjen et al.



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Rathjen, J; Yeo, C; Yap, C; Tan, BSN; Rathjen, PD; Gardner, DK

Title:

Culture environment regulates amino acid turnover and glucose utilisation in human ES cells

Date:

2014-01-01

Citation:

Rathjen, J., Yeo, C., Yap, C., Tan, B. S. N., Rathjen, P. D. & Gardner, D. K. (2014). Culture environment regulates amino acid turnover and glucose utilisation in human ES cells.

REPRODUCTION FERTILITY AND DEVELOPMENT, 26 (5), pp.703-716.

<https://doi.org/10.1071/RD12276>.

Persistent Link:

<http://hdl.handle.net/11343/51028>